We report a straightforward synthesis of a series of novel calcitriol analogues from vitamin D 2 with some modification of the procedures described by Calverley and Choudhry. This approach allows the large scale synthesis of a late-stage intermediate common to all the analogues of the series.This intermediate was successfully employed to synthesize a huge number of calcitriol analogues using a "click" chemistry approach.
Introduction
, the hormonally active metabolite of vitamin D 3 (2), acts as a regulator in calcium and phosphate homeostasis 1 . Next to these classical activities, calcitriol has been shown to inhibit cellular proliferation and to induce cellular differentiation 2 . However the therapeutic utility of 1 is hampered by the effective doses leading to calcemic side effects and this has stimulated the search for analogues having a relatively weak systemic effect on calcium metabolism while maintainig potent regulatory effects on cell differentiation and proliferation.
As part of our ongoing program on the synthesis of vitamin D analogues modified at the side chain, 3 we envisaged the synthesis of various calcitriol analogues having heteroatoms on their side chain. The rational that could explain this choice was: we have already synthesized and the biological activity of some of these derivatives was later studied showing that they had less calcemic effect than calcitriol. The strategy we used so far involved construction of the triene unit on the CD fragment following the introduction of the side chain. This strategy is inconvenient if a lengthy series of analogues with modified side chains are to be prepared for systematic biological evaluation. 
Results and Discussion
We examined the possibility of preparing a series of analogues modified at the side chain from a common intermediate, in which the labile triene system was already present. The use of this strategy involved the concept of the triene system protection to allow chemical modification of the vitamin D side chain. This concept received relatively little attention. 4 Among these approaches, the one using the preparation and subsequent thermolysis of the sulfur dioxide adducts of vitamin D 2 4b,c seemed to us more appropriate for a large scale synthesis of a latestage intermediate such as 10 (Scheme 1). Scheme 1.Synthesis of intermediate 10 from vitamin D 2 . Reagents and conditions: (i) a) SO 2 , CH 2 Cl 2 , -25 ºC to -10º C; b) TBSCl, cat. DMAP, CH 2 Cl 2 , -5º C to rt (97%, 2 steps); (ii) a) O 3 , CH 2 Cl 2 , MeOH, -78º C; b) PPh 3 , 0º C to 25º C; (iii) NaHCO 3 , EtOH, reflux; (iv) NaBH 4 , MeOH, 0º C (85% from 3); (v) Ac 2 O, Et 3 N, DMAP (96%); (vi) a) SeO 2 , MeOH, reflux; b) 7, NMO, 50º C (60 %); (vii) TBSCl, imidazole, DMAP, CH 2 Cl 2 (88%); (viii) K 2 CO 3 , MeOH (94%).
Accordingly vitamin D 2 was converted to its SO 2 -adducts 3 in 97% yield by dissolving in liquid sulfur dioxide and subsequent silylation. The ozonolysis of 3 resulted to be extremely troublesome and after much experimentation the best reaction conditions could be established. The results are summarized in Table 1 . The optimized reaction conditions for running the ozonolysis of 3 were as described in entries 4 and 5.
The time necessary for the ozonolysis to be completed was substrate dependant (1 h to ozonolyze 1 g of substrate 3). Aldehyde 4 was unstable and was immediately converted to alcohol 6 by thermal chelotropic extrusion of sulfur dioxide (SO 2 ) in the presence of sodium bicarbonate (NaHCO 3 ) followed by sodium borohydride reduction of the intermediate aldehyde 5. Alcohol 6 was obtained in 85% overall yield (3 steps) .
Reaction of alcohol 6 with acetic anhydride gave 96% yield of acetate 7 which was hydroxylated at C-1 with selenium dioxide in the presence of 4-methylmorpholine N-oxide (NMO) to afford allylic alcohol 8 in 60% yield. The latter was silylated, giving 88% yield of acetate 9. Reaction of the latter with potassium carbonate (K 2 CO 3 ) in methanol afforded key intermediate 10 with the 5-(E) triene system.
The overall yield of intermediate 10 from vitamin D 2 was 39%. Worth mentioning that the synthesis of 10 could be carried out in multigrams quantities and the compound could be stored in the fridge during months without alteration. Compound 10 is more stable than its 5-(Z) isomer and can be further elaborated in order to introduce the desired side chain.
The advantages of this present approach compared to Calverley and Choudhry's approaches are: 1) Only one SO 2 triene protection is needed, hence one SO 2 extrusion. 2) The ozonolysis of the side chain is carried out before the C-1 hydroxylation. 3) For the synthesis of 10 from vitamin D 2 , we found an overall yield of 39% which is a bit better then 37% calculated using Calverley's procedure.
We anticipated that intermediate 10 could lead to calcitriol analogues 15, 16, and 17 using a "Click" chemistry approach 5 between azide 11 and commercially available alkynes 12, 13, and 14. Our retrosynthetic basis is outlined in Scheme 2.
Scheme 2. Retrosynthetic analysis of analogues 15, 16 and 17 Accordingly compounds 15-17 were prepared as outlined in Scheme 3. Computational studies carried out by Sharpless and co-workers, 6 proved that the exclusive regioselectivity of the triazole formation could be explained by a stepwise mechamism involving unprecedented matallacycle intermediates (Figure 2 ). 
Conclusion
In conclusion, we have improved the method described by Calverley and Choudhry for the large scale synthesis of a late-stage intermediate which leads to a straightforward access to some calcitriol analogues with a triazole ring in their side chain. The use of intermediates mentioned above to access new calcitriol analogues is underway in our laboratory. The preliminary results of the biological activity of some of our azavitamin D analogues showed that they had less calcemic effect than calcitriol. These results as well as the activities of the whole series of the synthesized analogues will be published in due time after patent protection. is also gratefully acknowledged. A.F; M.S.; M.G. and O.D. thank the University Cheikh Anta Diop (Dakar, Sénégal) for financial support for a research stay at the University of Vigo.
Experimental Section

General Procedures
Solvents were purified and dried by standard procedures. Flash chromatography was performed on silicagel (Merck 60, 230-400 mesh). Analytical TLC was performed on plates precoated with silica gel (Merck 60 F254, 0.25 mm). Melting points were obtained using a Gallenkamp apparatus and are uncorrected. Optical rotations were obtained using a Jasco P-2000 polarimeter. IR spectra were obtained using a Jasco FT/IR-6100 Type A spectrometer.
1 H NMR (400 MHz) and 13 C NMR (100 MHz) spectra were recorded on a Bruker ARX-400 spectrometer using TMS as the internal standard; chemical shifts (δ) are quoted in ppm and coupling constants (J) in Hz. Mass spectrometry (MS and HRMS) was carried out using a Hewlett-Packard 5988A spectrometer. The reactions were carried out protecting the glassware from light using aluminum foil.
(6S)-6-((tert-butyldimethylsilyl)oxy)-1-((E)-((3aS,7aR)-1-((2R,5R,E)-5,6-dimethylhept-3-en-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)methyl)-1,3,4,5,6,7-hexahydrobenzo[c]thiophene 2,2-dioxide (3)
In a three neckround-bottom flask at -25 ºC was condensed SO 2 (100 mL, 2.00 mol) and a solution of vitamin D 2 (100 g, 0.25 mol) in CH 2 Cl 2 (250 mL) was added via cannula. At the end of the addition the orange mixture was stirred at -10 ºC for 90 min and allowed to reach room temperature, thus removing excess SO 2 . The solvent was evaporated and the residue was dissolved in CH 2 Cl 2 and cooled to 5 ºC. Imidazole (22.5 g, 0.33 mol), TBSCl (50 g, 0.33 mol) and a catalytic amount of DMAP were added to the mixture which was stirred overnight, reaching room temperature. H 2 O (100 mL) was added and the aqueous phase was extracted with CH 2 Cl 2 (3 x 25 mL). The combined organic phases were washed with brine (25 mL) and dried. Solvent evaporation afforded 140 g (96%) of known compound 3 4b .
(2S)-2-((3aS,7aR, E)-4-((E)-2-((S)-5-((tertbutyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol (6)
A solution of 3 (5 g, 8.7 mmol) in MeOH (66 mL) and CH 2 Cl 2 (170 mL) was subjected to ozonolysis using the best conditions described in Table 1 and after 5 h at -78º C the mixture was allowed to reach -10º C. PPh 3 (3 g, 11.5 mmol) was added and stirring was continued for 30 min. The mixture was allowed to reach 0 ºC and an aqueous saturated solution of NaHCO 3 (40 mL) was added. After extraction with CH 2 Cl 2 (3 x 100 mL), the combined organic phases were washed with brine (3 x 50 mL), dried (Na 2 SO 4 ), filtered and concentrated to give 4.43 g of a residue (aldehyde 4) which was used for the next reaction without further purification. The residue was dissolved in ethanol (45 mL) and NaHCO 3 (4.43 g) was added and the mixture was refluxed for 5 h. The solvent was rotatory evaporated affording a residue which was dissolved in CH 2 Cl 2 (25 mL) and filtered in order to remove excess NaHCO 3 . To the filtrate was added brine (50 mL). After extraction with CH 2 Cl 2 (3 x 25 mL), the combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated to afford a residue (compound 5) which was used for the next reaction without further purification. The residue was dissolved in MeOH (45 mL) and cooled to 0 ºC. NaBH 4 (400 mg, 10.44 mmol) was added portionwise to the mixture and stirring was continued for 15 min. H 2 O (50 mL) was added and the product extracted with CH 2 Cl 2 (3 x 50 mL). The combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 10% EtOAc/Hexane as eluent, affording 3.3 g (85% , 3 steps) of alcohol 6, as a white solid, M. 
(2S)-2-((3aS,7aR, E)-4-((E)-2-((S)-5-((tertbutyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propyl acetate (7)
To a solution of alcohol 6 (3.0 g, 6.75 mmol) in CH 2 Cl 2 (30 mL) were added pyr (1.2 mL, 14.8 mmol), Ac 2 O ( 0.7 mL, 7.43 mmol) and a catalytic amount of DMAP. The mixture was stirred for 2 h at room temperature and cooled to 0 ºC before adding an aqueous saturated solution of NH 4 Cl (30 mL). After extraction with CH 2 Cl 2 (3 x 40 mL), the combined organic phases were washed with an aqueous saturated solution of CuSO 4 (3 x 40 mL), dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 5% EtOAc/Hexane affording 2.9 g (94%) of acetate 7, as a yellowish oil; Rf = 0. 
(2S)-2-((3aS,7aR, E)-4-((E)-2-((3S,5R)-5-((tertbutyldimethylsilyl)oxy)-3-hydroxy-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propyl acetate (8)
A solution of SeO 2 (0.7 g, 6.32 mmol) in MeOH (50 mL) was refluxed for 45 min. A solution of acetate 7 (2.18 g, 4.47 mmol) in CH 2 Cl 2 (52 mL) was also refluxed for 15 min before adding it via cannula to the previous solution of SeO 2 . After the addition, the mixture was refluxed for 2 h and allowed to reach room temperature. H 2 O (10 mL) was added and the product extracted with CH 2 Cl 2 (3 x 25 mL). The combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 10% EtOAc/Hexane affording 1.37 g (61%) of alcohol 8, 
(2S)-2-((3aS,7aR,E)-4-((E)-2-((3S,5R)-3,5-bis((tertbutyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propyl acetate (9)
To a solution of alcohol 8 (1.90 g, 3.76 mmol) in CH 2 Cl 2 (10 mL), at 0 ºC was added imidazole (343 mg, 5.0 mmol), TBSCl (760 mg, 5.0 mmol) and a catalytic amount of DMAP and the mixture was left stirring at room temperature for 5 h. H 2 O (10 mL) was added and the product extracted with CH 2 Cl 2 (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 3% EtOAc/Hexane as solvent, affording 2.1 g (90%) of acetate 9, as a white solid, M. 2-((3aS,7aR, E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propan-1-ol (10) To a solution of acetate 9 (1.1 g, 1.83 mmol) in MeOH (30 mL) at room temperature was added K 2 CO 3 (500 mg, 3.67 mmol) and the mixture was stirred for 10 h. Excess K 2 CO 3 was eliminated by firtration and H 2 O (100 mL) was added to the filtrate and the product extracted with CH 2 Cl 2 (3 x 50 mL). The combined organic phases were washed with brine (3 x 20 mL), dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 3% EtOAc/Hexane as solvent, affording 990 mg (94%) of alcohol 10, as a white solid, M. 
(S)-2-((1R,3aS,7aR, E)-4-((E)-2-((3S,5R)-3,5-bis((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propyl 4-methylbenzenesulfonate (18).
To a solution of 10 (990 mg, 1.72 mmol) in Py (9 mL) at 0 ºC was added p-TsCl (660 mg, 3.44 mmol) and DMAP (c.c.) . The mixture was stirred at this temperature for 9 h, quenched with NH 4 Cl (10 mL), then allowed to reach room temperature. The product was extracted with EtOAc (3×15 mL). The organic phase was washed with CuSO 4 (3×20 ml).
After drying (Na 2 SO 4 ) and solvent evaporation, the residue was chromatographed on silicagel using 3% EtOAc-hexane as eluent, to afford 1. (1H, s, H-19), 4.48 (1H, m, H-1), 4.45  (1H, m, H-3), 3.92 (1H, m, H-22 (23) 
(((1R,3S,E)-5-((E)-2-((3aS,7aR)-1-((S)-1-azidopropan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diyl)bis(oxy))bis(tertbutyldimethylsilane) (11)
To a solution of tosylate 18 (933 mg, 1.28 mmol) in DMF (15 mL) was added NaN 3 (832 mg, 12.8 mol) and the mixture was stirred at room temperature for 42 h. CH 2 Cl 2 (25 mL) was added and the organic phase was washed with H 2 O (3 x 15 mL), dried (Na 2 SO 4 ), filtered and concentrated in vacuo to afford a residue which was chromatographed on silica gel using 5% EtOAc/Hexane as solvent, affording 750 mg (97%) of azide 11, as a white solid, M.p.: 104 ºC, Rf = 0.75 (10% EtOAc/Hexane); (1R,3S, E)-5-((E)-2-((3aS,7aR)-1-((S)-1- 
azidopropan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol (19)
To a solution of azide 11 (116 mg, 0.19 mmol) in THF (2 mL) was added TBAF (1.16 mL, 1.16 mmol, 1M sln in THF) and the mixture was stirred for 16 h. Aqueous saturated solution of NH 4 Cl (10 mL) was added and the product was extracted with EtOAc (3 x 10 mL). The combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 50% EtOAc/Hexane as solvent, affording 72 mg (99%) of azide 19, as a colourless oil, Rf = 0.11 (20% EtOAc/Hexane); To a solution of azide 19 (70 mg, 0.19 mmol) in tert-BuOH (2 mL) and H 2 O (1 mL) was added a catalytic amount of CuSO 4 .5H 2 O, sodium ascorbate (13υL of 1M aqueous sln), and the chosen alkyne (0.20 mmol). The mixture was stirred at room temperature for 7 h. H 2 O (10 mL) was added and the product was extracted with EtOAc (3 x 15 mL). The combined organic phases were dried (Na 2 SO 4 ), filtered and concentrated to afford a residue which was chromatographed on silica gel using 50% EtOAc/Hexane as solvent to afford the corresponding triazoles 20, 21 or 22. 2-((3aS,7aR)-1-((S)-1-(4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1 2-((3aS,7aR)-1-((S)-1-(4-(3-hydroxypentan-3-yl)-1H-1,2,3-triazol-1 Photosensitized isomerization of 20,21 and 22 to afford 15, 16 and 17, using anthracene as triplet sensitizer was carried out following the general procedure described for compound 20.
(1R,3S,E)-5-((E)-
To a solution of 20 (10 mg, 0.02 mmol) in MeOH (10 mL) was added anthracene (3 mg, 0.01 mmol) and a catalytic amount of Et 3 N. The mixture was irradiated with a 200 W lamp for 6 h, diluted with CH 2 Cl 2 (15 mL) and washed with brine (10 mL). After solvent evaporation the resulting residue was chromatographed on silica gel using CH 2 Cl 2 and 10% MeOH/CH 2 Cl 2 as solvent, affording 9 mg (90%) of analogue 15. 2-((3aS,7aR)-1-((S)-1-(4-(2-hydroxypropan-2-yl)-1H-1,2,3-triazol-1 
(1R,3S,Z)-5-((E)-
